Statin-based treatment for cardiovascular risk and non-alcoholic fatty liver disease. Killing two birds with one stone?
Loading...
Date
Authors
Athyros, V. G.
Tziomalos, K.
Daskalopoulos, G. N.
Karagiannis, A.
Mikhailidis, D. P.
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Type
Type of the conference item
Journal type
peer-reviewed
Educational material type
Conference Name
Journal name
Ann Med
Book name
Book series
Book edition
Alternative title / Subtitle
Description
Cardiovascular disease (CVD) and non-alcoholic fatty liver disease (NAFLD) share common risk factors and may have a parallel course. Statin treatment alone or in combination with other drugs has a substantially beneficial effect on CVD morbidity and mortality. The question was if these regimens were harmful for the liver. Mounting data suggest that statin monotherapy or statin-based treatments are safe in patients with NAFLD and can improve liver tests and liver ultrasonographic evidence of NAFLD. Recent data suggest that statin-based therapies are beneficial to the liver and at the same time reduce CVD morbidity and mortality in patients with NAFLD more than in subjects without it. These findings suggest that with statins we are able to get two birds with one stone.
Description
Keywords
Animals, Cardiovascular Diseases/etiology/*prevention & control, Fatty Liver/drug therapy/etiology, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology/*therapeutic use, Liver Function Tests, Risk Factors
Subject classification
Citation
Link
http://www.ncbi.nlm.nih.gov/pubmed/21476786
http://informahealthcare.com/doi/abs/10.3109/07853890.2011.561363
http://informahealthcare.com/doi/abs/10.3109/07853890.2011.561363
Language
en
Publishing department/division
Advisor name
Examining committee
General Description / Additional Comments
Institution and School/Department of submitter
Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής